Today on the Daily Dive, we get the opportunity to sit down with Bruce Linton, founder and former CEO of Canopy Growth Corp, and an advisor to Creso Pharma (ASX: CPH), among numerous others. Bruce sits down with us to talk legalization south of the border, psychedelics, and the firms he advises, including Gage Cannabis and Creso Pharma.
Creso Pharma is an ASX-listed issuer with operations focused on the use of cannabis and hemp across Canada, Europe, Latin America and Australia. In Canada, the company operates its licensed producer, Mernova Medicinal, in Nova Scotia, which focuses on high quality cannabis production. It’s European operations meanwhile are based in Switzerland, where it focuses on its Animal Health, Nutraceutical, and Cosmetics divisions.
Catch the full interview below.
FULL DISCLOSURE: Creso Pharma is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Creso Pharma on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.